Company:Evogene
 | This article needs additional citations for verification. (December 2020) (Learn how and when to remove this template message) |
 | |
| Type | Public |
|---|---|
| TASE: EVGN NYSE: EVGN | |
| Industry | Computational Biology |
| Founded | 2002 |
| Founder | Dr. Hagai Karchi and Dr. Rafi Meissner |
| Headquarters | Rehovot, Israel |
Key people | Martin Gerstel, Chairman of Board, Ofer Haviv, President & CEO |
| Subsidiaries | Biomica, Canonic, Lavie Bio, AgPlenus, Castera |
| Website | www |
Evogene is a computational biology company based in Israel. Evogene Ltd. (NASDAQ:EVGN) has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence ("AI"), while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficacy and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF (OTCQX:BASFY), Bayer (OTCPK:BAYZF), Corteva (CTVA), ICL Group Ltd. (ICL) as well as various academic and medical institutions.
 | This article uses only URLs for external sources. (2021) (Learn how and when to remove this template message) |
 |  |
